WT161 is used in research settings as a selective inhibitor of the WEE1 kinase, a key protein involved in cell cycle regulation. By inhibiting WEE1, WT161 promotes premature entry of cancer cells into mitosis, especially in cells with p53 deficiencies, leading to increased DNA damage and cell death. This makes it a valuable tool in oncology research, particularly in studies focused on targeted cancer therapies and synthetic lethality approaches. It is often used in combination with DNA-damaging agents such as chemotherapy or radiation to enhance their cytotoxic effects in tumor cells. Due to its mechanism, WT161 is studied for potential applications in treating cancers with specific genetic backgrounds, including certain types of ovarian, lung, and colorectal cancers.